REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.90
Bid: 13.80
Ask: 14.00
Change: 0.30 (2.21%)
Spread: 0.20 (1.449%)
Open: 13.60
High: 13.90
Low: 13.60
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Chill Brands unphased by regulations; Cobra inks deal

Tue, 19th Sep 2023 14:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says that the opposition to Immunomodulator I, one of its European patents, which was previously filed by a third party is to be withdrawn. Explains that, further to engaging with the opposing party, it has reached an amicable conclusion in relation to the patent dispute without any financial compensation between the parties. This has resulted in the opposing party agreeing to withdraw its opposition to the Immunomodulator I European patent and agreeing not to challenge any of Poolbeg's Immunomodulator I or Immunomodulator II patents in the future. Subsequently, Poolbeg will be communicating with the European Patent Office regarding the necessity of continuing with the scheduled hearing in November.

----------

Chill Brands Group PLC - Colorado, US-based CBD products company - Says that talks with retailers are ongoing and "constructive", despite recent UK regulations targeting vaping. Notes that it "welcomes" measures to improve industry social responsibility, and reduce the prevalence of underage vaping, adding that it is "clearly important that steps are taken to safeguard children". Says that shareholders can take comfort that the business is agile and well-equipped to accommodate any regulatory changes that come to pass. Chill Brands also says that it has already worked with its manufacturing partners to design discreet reusable vapour devices, which mirror the look and feel of a disposable vape but accommodate pre-filled e-liquid cartridges that can be replaced at will without the need to dispose of the battery unit.

----------

Cobra Resources PLC - Gold, rare earth and iron oxide copper gold ore deposits exploration company focused on the Wudinna project in South Australia - Signs a memorandum of understanding with Watercycle Technologies Ltd, a UK-based deep tech company focused on developing sustainable, high-yield, low-cost, mineral extraction and water treatment systems. Under the agreement, both companies will collaborate on sustainable rare earth elements extraction via membrane desorption and filtration. Says that the memorandum is the first step in forming a partnership to progress the process for REE extraction from the company's Boland ionic REE discovery, where innovation and flowsheet development will form the basis of commercialisation.

----------

Begbies Traynor Group PLC - Manchester, England-based business recovery, financial advisory and property services consultancy - Says that the last financial year was "another successful year of further growth". Says its performance came from broadening its range of services to "an increasingly diverse" range of clients. Adds that at this early stage of the financial year, the firm's expectations remain unchanged and it is confident of delivering market expectations for the full year. Analyst forecasts are currently predicting adjusted profit before tax of GBP21.9 million to GBP22.5 million. Begbies says that with 80% of income generated from counter-cyclical and defensive activities, it remains well-positioned in the current challenging economic environment. Executive Chair Rick Traynor adds: "Overall, the group remains in a strong financial position and well placed to continue to invest in the business, both organically and through acquisitions, to further build our scale and range of complementary services."

----------

Unicorn Mineral Resources PLC - Irish mineral exploration company, focused on exploration for carbonate-hosted copper, lead, zinc, and silver mineral deposits in the Irish Midlands ore field - Says that visual interpretation of the initial core samples from the drilling at its flagship Kilmallock project indicated a major fault zone running approximately North to South and dipping steeply to the East. After receiving this data, Unicorn revised the drill programme to confirm the geological model. It expects results back from this testing by the end of September, and says that until these have been received, the company is not in a position to give any definitive information on what the drilling indicates or the grade of any mineralisation discovered. However, notes that a visual inspection of the cores does indicate mineralisation, which looks to be analogous to that seen at the Pallas Green system. The board are sufficiently encouraged by the initial analysis to be planning an orientation survey, to take place in October and November, to the South and South-East of the current drilling.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.